Inbec疗效怎么样呢？

Inbec (Inbec) is a drug for the treatment of AIDS. Inbec (Inbec) is currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

In 2018, GSK announced the launch of the integrase DTG (Inbec) in China. This treatment has the advantages of small drug dosage, resistance to drug resistance, and low probability of drug side effects. Inbec uses DTG, an integrase inhibitor, as the core drug, and combines it with abacavir and lamivudine as a treatment plan. It is made into a single-tablet treatment and promoted, making the core drug a great progress in HAART treatment. In addition, this treatment agent can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line treatment of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), Inbec (Inbec) has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance.

Suimeike () has been approved in more than 100 countries and has been recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the lifespans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time, on the Chinese market. The approval of Inbec fills this gap and meets the urgent need for convenient medication use by doctors and patients."